drugset / Trial / NCT05411432
Clinical Study of 68Ga Labeled HER2 Affibody Analogues
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to assess the dosimetric properties of the positron emission tomography (PET) imaging probe 68Ga labeled HER2 Affibody analogues and preliminarily evaluate its diagnosis value in patients with breast or gastric tumors.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2023-06-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga labeled HER2 Affibody | Diagnostic / imaging agent | 4.93 unknown | — |